News | January 10, 2019

Mobile App Data Collection Shows Promise for Population Health Surveys

Researchers evaluate Medable Inc.’s mobile health survey solution as potential way to eliminate barriers to large-scale data collection

Mobile App Data Collection Shows Promise for Population Health Surveys

January 10, 2019 — Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study timeframes and create more comprehensive sample sizes, according to research published in Survey Practice.

“It is critical that health and other national surveys represent the voice and experience of all Americans,” said senior author Ingrid Oakley-Girvan, senior vice president of research and strategy at Medable Inc., research director at the Public Health Institute, and associate member of the Canary Center at Stanford for Cancer Early Detection and the Stanford Cancer Institute. “Smartphone survey data can help policy makers allocate resources in realtime to respond to disease outbreaks such as opioid addiction. Our work sheds light on the value of smartphones to address declining participation rates, rising survey costs and poor coverage across demographics.”

Oakley-Girvan and co-authors Yasamin Miller, Cyrus DiCiccio, Juan Lavista, Cheryl Gore-Felton, Amanda Richardson, Carlos Acle, Jeff Hancock, Lorene Nelson and Oxana Palesh were interested in the impact that smartphones can have on health data survey collection.

They studied the response to a mobile app survey, built on the Medable Inc. platform, by deploying it in a college student population to determine if students would download the app, and to determine if the app would retain individuals in a study, two significant barriers being faced by researchers conducting population health surveys.  

“Our findings show that mobile app data collection can fundamentally change survey research,” said Miller, first author and founder and managing director of YMG. “Using mobile apps could create a shift in health surveys, which could eventually lead to faster and more accurate health policies and cures.”

Declining response rates to traditional telephone surveys are hindering researchers in their abilities to recruit and study the most pressing medical issues. The study used Medable Inc.’s platform to provide efficient real-world data collection, monitoring and analysis.

The researchers partnered with faculty from Stanford University, the Cancer Prevention Institute of California (CPIC), OneTree, YMG and Castleton University, to leverage Medable’s platform to collect behavioral health and substance use data. The researchers built and deployed two apps in under six weeks.

Medable’s end-to-end (E2E) platform enables researchers without developer expertise to create and deploy HIPAA-compliant iOS and Android apps for clinical trials or research studies. “Creating mobile applications on a short timeline would not have been possible without the use of Medable’s Axon,” said Miller. “Medable’s platform enabled team members without coding expertise to contribute and play key roles in developing the study.”

For more information: www.medable.com

Reference

Related Content

News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
Subscribe Now